1,5-dideoxy-1,5-[[2-[4-(ethoxycarbonyl)phenoxy]ethyl]imino]-D-glucitol
- Product Name
- 1,5-dideoxy-1,5-[[2-[4-(ethoxycarbonyl)phenoxy]ethyl]imino]-D-glucitol
- CAS No.
- 80879-63-6
- Chemical Name
- 1,5-dideoxy-1,5-[[2-[4-(ethoxycarbonyl)phenoxy]ethyl]imino]-D-glucitol
- Synonyms
- MKC-542;BAY-o-1248;Emiglitate;1,5-dideoxy-1,5-[[2-[4-(ethoxycarbonyl)phenoxy]ethyl]imino]-D-glucitol;1,5-dideoxy-1,5-[[2-[4-(ethoxycarbonyl)phenoxy]ethyl]imino]-D-glucitol USP/EP/BP;4-[2-[(2R,3R,4R,5S)-3,4,5-Trihydroxy-2-(hydroxymethyl)piperidino]ethoxy]benzoic acid ethyl ester;Benzoic acid, 4-[2-[(2R,3R,4R,5S)-3,4,5-trihydroxy-2-(hydroxymethyl)-1-piperidinyl]ethoxy]-, ethyl ester
- CBNumber
- CB7924534
- Molecular Formula
- C17H25NO7
- Formula Weight
- 355.38
- MOL File
- 80879-63-6.mol
1,5-dideoxy-1,5-[[2-[4-(ethoxycarbonyl)phenoxy]ethyl]imino]-D-glucitol Property
- Boiling point:
- 580.2±50.0 °C(Predicted)
- Density
- 1.328±0.06 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- solubility
- Soluble in DMSO
- form
- Solid
- pka
- 13.68±0.70(Predicted)
- color
- White to off-white
N-Bromosuccinimide Price
- Product number
- API0011315
- Product name
- EMIGLITATE
- Purity
- 95.00%
- Packaging
- 5MG
- Price
- $503.92
- Updated
- 2021/12/16
1,5-dideoxy-1,5-[[2-[4-(ethoxycarbonyl)phenoxy]ethyl]imino]-D-glucitol Chemical Properties,Usage,Production
Description
Emiglitate (BAY O 1248), another deoxynojirimycin analogue is characterized by at least five-fold higher inhibitory potency than acarbose and additionally shows a long-lasting inhibitory effect. In animal studies emiglitate was still active up to 17 h after a single oral administration due to its pharmacokinetic behavior (formation of an active metabolite). Both miglitol and emiglitate differ in their pharmacokinetic behavior from acarbose, which is poorly absorbed (1 – 2 %). The deoxynojirimycin derivatives are structurally related to monosaccharides and will be absorbed in the jejunum.
Uses
Emiglitate (BAY o 1248) is a potent, selective and competitive inhibitor of α-glucoside hydrolase.
in vivo
In fasted rats, emiglitate inducec a significant, dose-dependent increase of hepatic glycogen concentrations. The increase in hepatic glycogen is due to lysosomal storage of glycogen only. Emiglitate in the amount of 5 mg/kg b.wt. does not induce significant changes either of glycogen concentrations or at the EM-level[2].
References
[1] Mosén H, et al. Nitric oxide inhibits, and carbon monoxide activates, islet acid alpha-glucoside hydrolase activitiesin parallel with glucose-stimulated insulin secretion. J Endocrinol. 2006 Sep;190(3):681-93. DOI:10.1677/joe.1.06890
[2] Lembcke B, et al. Lysosomal storage of glycogen as a sequel of alpha-glucosidase inhibition by the absorbed deoxynojirimycin derivative emiglitate (BAYo1248). A drug-induced pattern of hepatic glycogen storage mimicking Pompe's disease (glycogenosis type II). Res Exp Med (Berl). 1991;191(6):389-404. DOI:10.1007/BF02576694
1,5-dideoxy-1,5-[[2-[4-(ethoxycarbonyl)phenoxy]ethyl]imino]-D-glucitol Preparation Products And Raw materials
Raw materials
Preparation Products
1,5-dideoxy-1,5-[[2-[4-(ethoxycarbonyl)phenoxy]ethyl]imino]-D-glucitol Suppliers
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
- Country
- United States
- ProdList
- 32435
- Advantage
- 58
- Tel
- +1-708-310-1919 +1-13798911105
- Fax
- 708-557-7486
- sales@invivochem.cn
- Country
- United States
- ProdList
- 6391
- Advantage
- 58
- Tel
- +17819995354
- marketing@targetmol.com
- Country
- United States
- ProdList
- 19961
- Advantage
- 58
- Tel
- --
- Fax
- --
- sales@medchemexpress.com
- Country
- United States
- ProdList
- 6398
- Advantage
- 58